Ciprofloxacin hydrochloride usp msds

Search and buy. Your confidence in your work is bolstered by your confidence in your standards. USP Reference Standards are rigorously tested and evaluated by multiple independent commercial, regulatory, and academic laboratories to confirm accuracy and reproducibility. We offer publicly available, official documentary standards for pharmaceutical ingredients in the USP—NF that link directly with a primary reference standard.

When you use these standards together, you can be assured that your product meets compliance requirements and establish the quality benchmark against which you compare your results.

ciprofloxacin hydrochloride usp msds

We take a collaborative and rigorous approach to ensure USP Reference Standards reflect the highest quality in the industry — because helping you comply with quality requirements is one of our chief goals. Learn more about the process. Our new and updated monographs and official USP Reference Standards support your need to use evolving technologies and new innovations in manufacturing quality medicines.

See the new releases. USP regularly tests the standards you use to ensure that they remain up-to-date and suitable for your compendial needs. Learn more. Our monthly newsletter provides timely information on the latest Reference Standard releases, publication announcements, education courses, helpful tips and answers to FAQs.

Sign up now. Our expert staff and USP training resources are available worldwide to help you choose the best products for your needs, provide technical information on official USP Reference Standards and USP—NF monographs, inform you about new products and share resources and insights to facilitate your work. Build your expertise. Browse our support topics.

Find your regional account manager. Get contact information for our Technical Services team. Technical services and account managers. See the team. Breadcrumb Home Our Work. Reference Standards. Get access to new features, an updated design and more. Sign up for the latest news on standards, products, services and activities. Get answers to your questions about using USP standards.

Stay informed of new official text, notices, commentary, errata and more! Get customer support at every step to enable your success. Want to connect with your USP regional account manager?We can also offer its intermediates with supportive technical package required for evaluation. Please click here to send an email. Hence it would be most beneficial for you to visit the website again and again till you gain!

Our customers expect a prompt response on both the quotes and delivery of the product. As a general rule, we respond to new enquiry within 48 hours after the initial screening of product availability and supply ability if the material is not in stock. If any project is initiated already, we provide each customer with a report as to when we can offer you the requested product along with the actual status of the synthesis of the project.

Important COVID-19 information for USP Reference Standards customers

This facilitates real-time feedback to our customers. We listen carefully to our customer's concerns and needs and address each of their requirements promptly and effectively. Advanced Search. Recommended - 1-Butylmethylimidazolium tetrafluoroborate - Ipratropium Bromide - Perampanel - Nortestoterone decanoate.

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.

Ciprofloxacin hydrochloride CAS No. CAS number: Chemical Name: 1-Cyclopropylfluoro-1,4-dihydrooxo 1-piperazinyl quinolinecarboxylic acid hydrochlorideCiprofloxacin hydrochloride CAS No. Please enter Email Address.

Please enter Your Name. Properties Related Intermediates Synonym. Molecular Formula. Molecular Weight.

Important COVID-19 information for USP Reference Standards customers

Material Safety Data Sheet. Manus Aktteva makes no representations or warranties of any kind, express or implied, about the originality or reliability with respect to the intellectual property which includes patents in its products or services for any purpose. Manus Aktteva Biopharma LLP warns the sellers not to sell any goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual. Please click here to send us sourcing request.

ciprofloxacin hydrochloride usp msds

Why Us. Quick Links. Request a Quote. Request a Conversation. Click here. Follow us on.JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website. Unsure about this product? Canada Canada USA. Products Antibiotics Liquid. Gel Electrophoresis. Heat Baths. Hot Plate Stirrers. Thermal Cyclers. Vacuum Aspirators. Vacuum Manifolds.

Water Baths.

Ciprofloxacin

Cell Counting. Biological Buffers. Biology Reagents. Enzyme Inhibitors. Growth Regulators. Protein Expression. Water - Culture Grade. Blotting Papers. Ethidium Bromide Disposal. Ladders - RNA. Ladders - DNA. Ladders - Protein. Precast Gels. Reducing Agents. Tracking Dyes. Culture Related. Filtration Supplies. Lab Safety Equipment. Lab Supplies.The inactive ingredients are boric acid, sodium chloride, hydroxyethyl cellulose, tyloxapol, acetic acid, sodium acetate, edetate disodium, and purified water.

ciprofloxacin hydrochloride usp msds

Sodium hydroxide or hydrochloric acid may be added for adjustment of pH. Ciprofloxacin, a fluoroquinolone is available as the monohydrochloride monohydrate salt of 1-cyclopropylfluoro-1,4-dihydrooxo 1-piperazinyl qui nolinecarboxylic acid.

The empirical formula is C 22 H 29 FO 5 and the structural formula is:. Peak plasma concentrations ranged from 0. Peak plasma concentrations of ciprofloxacin were observed within 15 minutes to 2 hours post dose application. Peak plasma concentrations of dexamethasone were observed within 15 minutes to 2 hours post dose application. Dexamethasone has been added to aid in the resolution of the inflammatory response accompanying bacterial infection such as otorrhea in pediatric patients with AOM with tympanostomy tubes.

Microbiology: Ciprofloxacin has in vitro activity against a wide range of gram-positive and gram-negative microorganisms. The bactericidal action of ciprofloxacin results from interference with the enzyme, DNA gyrase, which is needed for the synthesis of bacterial DNA.

Cross-resistance has been observed between ciprofloxacin and other fluoroquinolones. There is generally no cross-resistance between ciprofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides. Acute Otitis Media in pediatric patients age 6 months and older with tympanostomy tubes due to Staphylococcus aureusStreptococcus pneumoniaeHaemophilus influenzaeMoraxella catarrhalisand Pseudomonas aeruginosa. Acute Otitis Externa in pediatric age 6 months and olderadult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa.

Use of this product is contraindicated in viral infections of the external canal including herpes simplex infections. Serious and occasionally fatal hypersensitivity anaphylactic reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Serious acute hypersensitivity reactions may require immediate emergency treatment. As with other antibacterial preparations, use of this product may result in overgrowth of nonsusceptible organisms, including yeast and fungi.

If the infection is not improved after one week of treatment, cultures should be obtained to guide further treatment. If otorrhea persists after a full course of therapy, or if two or more episodes of otorrhea occur within six months, further evaluation is recommended to exclude an underlying condition such as cholesteatoma, foreign body, or a tumor. The systemic administration of quinolones, including ciprofloxacin at doses much higher than given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species.

For otic use only.Generic Name: Ciprofloxacin hydrochloride Dosage Form: tablet, film coated. Medically reviewed by Drugs.

Last updated on Sep 1, Ciprofloxacin tablets are indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescensor Pseudomonas aeruginosa. Ciprofloxacin tablets are indicated in adult patients for treatment of complicated intra-abdominal infections used in combination with metronidazole caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.

Ciprofloxacin tablets are indicated in adult patients for treatment of typhoid fever enteric fever caused by Salmonella typhi. The efficacy of Ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Ciprofloxacin tablets are indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see Warnings and Precautions 5. Ciprofloxacin tablets are indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax post-exposure to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.

Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication. Ciprofloxacin tablets are indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis Y.

Efficacy studies of Ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see Clinical Studies Ciprofloxacin tablets are indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis.

Ciprofloxacin tablets are indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Ciprofloxacin tablets are not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.

Ciprofloxacin tablets are indicated for the treatment of acute exacerbations of chronic bronchitis AECB caused by Moraxella catarrhalis. Urinary Tract Infections in Adults. Ciprofloxacin tablets are indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis.

Ciprofloxacin tablets are indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. Ciprofloxacin tablets are indicated in pediatric patients aged one to 17 years of age for treatment of complicated urinary tract infections cUTI and pyelonephritis due to Escherichia coli [see Use in Specific Populations 8.

Ciprofloxacin tablets are indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin tablets and other antibacterial drugs, Ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to Ciprofloxacin. Therapy with Ciprofloxacin tablets may be initiated before results of these tests are known; once results become available appropriate therapy should be continued.

As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Ciprofloxacin.

Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.Search and buy Reference Standards. Help ensure the quality and consistency of biological treatments reaching patients globally. See the list. More than dietary supplements reference standards are available. See the newly released botanical reference standards.

USP recognizes the continuing increase in industry cost. This coming year, USP expects to see our own costs increase due to our continued investment in global public health.

However, we will not take a general price increase at this time. USP reserves the right to make adjustments on a case by case basis, should conditions change. We thank you for your continued support of USP efforts to help ensure the quality of medicines, foods and dietary supplements and provide industry with the products and services you need, at a fair value.

Product-specific standards and performance standards for Biologics Help ensure the quality and consistency of biological treatments reaching patients globally. New dietary supplements Reference Standards More than dietary supplements reference standards are available.

Value beyond the vial. The development process. Ordering information and subscriber resources.Available for download Document available for download after approval of supplier Set as available by supplier but document not uploaded yet.

Ciprofloxacin Hydrochloride manufacturers traders suppliers We have 19 companies offering Ciprofloxacin Hydrochloride from 4 different countries.

ciprofloxacin hydrochloride usp msds

Let the supplier know whether you are looking for a product with a specific monograph such as EP Ph. Or, whether you are looking for hydrochloride HClanhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers.

Important COVID-19 information for USP Reference Standards customers

Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer. Register for free. Safe transaction with Pharmaoffer Secure payment. Toggle navigation. Home Raw materials Ciprofloxacin Hydrochloride. Filters Results. Type Producer. Country of origin China. Qualifications CoA. Send inquiries for free and get in direct contact with the supplier of your choice. Type: Producer Origin: India.

Send inquiry. Sun Pharma. Neuland Labs. Aarti Drugs. Shaoxing Hantai Pharma. Type: Trader Origin: China. Type: Producer Origin: Germany.

Ciproflox,ciprofloxacin 500mg ,antibiotic tablet, घाव कैसे ठीक करे, बुखार की टेबलेट,fever ki tablet

Ningbo Hi-tech Biochemicals Co Ltd. Type: Producer Origin: China. Zhejiang Guobang. Zhejiang Huayi. Uquifa Mexico. Type: Producer Origin: Mexico. Quimica Sintetica. Type: Producer Origin: Spain. Sreepathi Pharma. Emmennar Pharma. Zhejiang Langhua. Shangyu Jingxin.


Comments

Leave a Comment

Your email address will not be published. Required fields are marked *